How would you manage BCR-ABL CML that is resistant to imatinib, with concurrent JAK2 mutation?

As Dr. Tremblay mentioned, it’s important to separate the JAK2 component from CML. If the patient truly has a JAK2 mutant MPN, I would treat it depending on what the manifestations of that disease are.

On the CML front, I would manage the imatinib resistance the same way you would any other patient....

This is an interesting situation that occasionally comes up when a Ph+ CML clone will coexist with a Ph- MPN. It’s important to determine how prominent the JAK2 mutation is and if it represents true disease or CHIP.

In these cases, I recommend concurrent management, understanding that combined thera...